Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 9Prostatic Neoplasms 7Recurrence 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Squamous Cell 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 4Melanoma 4Liver Neoplasms 4Endometrial Neoplasms 4Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Hematologic Neoplasms 3Fatigue 3Esophageal Neoplasms 3Depression 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2

Interventions

eculizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Optic Neuritis × Clear all
NCT04155424 2024-09-25

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

Alexion Pharmaceuticals, Inc.

Phase 2/3 Terminated
5 enrolled 15 charts

Demyelinating Diseases, Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡